2026 Final Rate Announcement for MA and Final Part D Program Instructions

April 9, 2025

EGWP medicaid Medicare

On April 7, CMS released the Calendar Year (CY) 2026 MA and Part D Final Rate Announcement and the Final CY 2026 Medicare Part D Program Instructions. The Administration strongly defended its focus on fraud, waste, and abuse, while protecting beneficiaries. The final rate notice increases average payments to MA plans by 5.06% up from the proposed 2.23%. The primary driver of higher payments for 2026 is CMS’ projection of higher cost trends in fee-for-service (FFS), which reflects more recent data.

CMS also finalized various technical adjustments and risk adjustment policy changes that reduce payments, leading to rates that will likely remain below the cost of caring for seniors in 2026. As expected, CMS will complete the phase-in of the new MA risk adjustment model that began in 2024. CMS also finalized the method for “normalization,” which alters risk adjustment payments to reflect FFS risk score trends. The combined impact of these policies is an estimated reduction in payments of 3.01%, on average.

Separately, CMS did not raise the coding intensity adjustment above the minimum 5.91% required by statute. CMS will implement updates to the Part D risk adjustment models for CY 2026 reflecting changes by the IRA to the Part D benefit for CY 2026, including the continuation of the Manufacturer Discount Program, the updated out-of-pocket threshold, and negotiated prices for selected drugs under the Medicare Drug Price Negotiation Program.

CMS also indicated it would carefully evaluate the feasibility and timing of any future changes to base the risk adjustment model on MA encounter data rather than FFS data and acknowledged requests for an extended comment period and transparency if a new model is formally proposed. 

legislation

Virginia and Hawaii Introduce PDAB Legislation

The Virginia Senate introduced a bill to establish a Prescription Drug Affordability Board (PDAB) to review drugs with a wholesale acquisition cost (WAC) of $60,000 or more per year or a WAC increase of $3,000 or more in any 12-month period. For drugs deemed to cause an affordability challenge, the legislation authorizes the PDAB to […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

Solutions

AHIP Shares Update on Plan Progress to Simplify Prior Authorization

AHIP shared progress on the voluntary, multi-year commitments made by AHIP, BCBSA, and leading health plans (including Cigna Healthcare) to streamline and simplify prior authorization. Health plans serving nearly 270 million Americans are participating in this initiative. The 2026 commitments took effect on Jan. 1 and include: reducing the scope of claims subject to prior […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

legislation

DOL Issues Proposed Rule on Improving Transparency into PBM Fees

Pursuant to President Trump’s Executive Order “Lowering Drug Prices by Once Again Putting Americans First,” the Department of Labor’s (DOL’s) Employee Benefits Security Administration (EBSA) issued a proposed rule that would require providers of PBM services and affiliated entities of brokerage and consulting services to disclose direct and indirect compensation to their self-funded ERISA fiduciary […]
read more >

February 12, 2026

EGWP marketplace medicaid Medicare

You may also like